Celcuity Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Celcuity announced FDA approval of REVTORPYK (gedatolisib) on July 14, 2026, for HR+/HER2- PIK3CA wild-type advanced breast cancer, with commercial launch planned late Q3 2026. The company raised $557.2M net proceeds from a $575M convertible notes offering (0.250% due 2032) and used $137M to prepay term debt. Phase 3 VIKTORIA-1 PIK3CA mutant cohort showed gedatolisib reduced disease progression/death risk 50% vs. alpelisib (HR=0.50; median PFS 11.1 vs. 5.6 months), with sNDA planned Q3 2026. SG&A expenses surged $27.4M YoY to $35.0M in Q2 2026, driven by $23.4M in commercial hiring and launch preparation. Cash position stands at $754M as of June 30, 2026, expected to fund operations into 2029.
Why this rating
First FDA approval transformational for pre-revenue biotech ($457.5M market cap). $557M raise and strong cash runway are material. Commercial launch late Q3 2026 is business-critical inflection. Positive Phase 3 data supports label expansion potential. Magnitude meaningful but execution risk remains.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.